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Abstract Insulin-like growth factor binding protein-3, IGFBP-
3, speci¢cally binds to IGFs with high a⁄nity, but it is also
capable of modulating the IGF-I signalling pathway or inducing
apoptosis independently of its binding to IGFs. The molecular
mechanisms underlying the action of IGFBP-3 have not been
elucidated. In this study, we have demonstrated that binding of
IGFBP-3 to a cell surface receptor in MCF-7 breast carcinoma
cells induces a rapid and transient increase in intracellular free
calcium. This increase was mediated via a pertussis toxin-sensi-
tive pathway, indicating that the IGFBP-3 receptor may be
speci¢cally coupled to a Gi protein. The e¡ect of IGFBP-3 on
calcium concentrations was dose-dependent and also occurred
when IGFBP-3 was complexed with either IGF-I or heparin,
suggesting that the receptor binding site is probably located in
the least conserved central domain of IGFBP-3. Neither
IGFBP-1, nor IGFBP-5 (structurally the closest to IGFBP-3)
altered intracellular calcium concentrations. These results pro-
vide evidence that a speci¢c intracellular signal is triggered by
IGFBP-3 binding to a cell surface receptor. . 2002 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
Key words: Insulin-like growth factor binding protein-3;
Intracellular calcium; Breast carcinoma cell ;
Gi protein-coupled receptor
1. Introduction
The insulin-like growth factors, IGF-I and -II, participate
in regulating proliferation and/or di¡erentiation in diverse cell
types via the type I IGF receptor (IGF-IR) (reviews in [1,2]).
In all biological £uids, they are associated with high-a⁄nity
binding proteins, the IGFBPs, which act as carriers and mod-
ulate the availability of IGFs to their target cells [1,3,4]. One
of these six IGFBPs, IGFBP-3, is present in most tissues [5]
and is known to possess intrinsic activities that are unrelated
to its IGF binding ability (review in [6]). These activities re-
quire binding to a speci¢c cell surface receptor [7], but the
nature of the latter and the signalling pathways that it acti-
vates remain unknown. These ‘IGF-independent’ e¡ects of
IGFBP-3 play a direct role in cell growth [8,9], they induce
apoptosis [10] and they modulate IGF signalling [11]. Identi-
¢cation of the molecular mechanisms underlying the action of
IGFBP-3 is therefore of primary importance.
One route would be to identify other events required for
these e¡ects and investigate a link with the in£uence of
IGFBP-3-induced signalling. An increase in free cytosolic cal-
cium is a key signal in the induction of apoptosis and IGFBP-
3 has been shown to induce apoptosis directly [10] and/or to
potentiate the e¡ects of apoptotic agents [12,13]. We therefore
investigated the possibility that IGFBP-3 may alter calcium
levels in MCF-7 breast carcinoma cells and provide some clue
as to the signalling pathways activated by IGFBP-3.
2. Materials and methods
2.1. Radioiodination of IGFBP-3
(N109D)-rhIGFBP-3 (Upstate Biotechnologies) was labelled by the
chloramine-T method using Na 125I (Amersham) and puri¢ed by gel
¢ltration in a 0.1 M acetic acid, 0.15 M NaCl solution. Speci¢c ac-
tivity was approximately 100 WCi/Wg IGFBP-3.
2.2. Binding of IGFBP-3 to the cell surface
The method used was similar to that described by Yamanaka et al.
[14]. Con£uent monolayers of MCF-7 cells (V1.7U106 cells/well)
were incubated in serum-free medium for 16 h. The cells were washed
once with cold HBSS (Hanks’ balanced salt solution without CaCl2
and MgCl2, containing 25 mM HEPES, pH 7.4 and 25 mM
NaHCO3). Cell surface-bound endogenous IGFBPs were then re-
moved by rinsing the cells once in cold HBSS containing 1 mM
EDTA. The cells were then washed once in cold HBSS and incubated
in 600 Wl binding bu¡er (HBSS containing 1 mM CaCl2 and 0.5%
bovine serum albumin (BSA)) for 4 h at 4‡C with [125I]IGFBP-3
(V50 000 cpm) in the absence (triplicate) or in the presence (dupli-
cate) of varying concentrations of unlabelled IGFBP-3 (and 400 nM
in triplicate for determination of non-speci¢c binding). They were
then washed three times in cold phosphate-bu¡ered saline (PBS)
and solubilized with 0.5 M NaOH. Radioactivity of the cell lysates
was measured in a Q-counter and speci¢c binding was determined by
subtracting non-speci¢c binding from total counts.
2.3. Determination of intracellular free Ca2+ concentration
Changes in intracellular Ca2þ concentration in response to IGFBP-
3 were measured using a QuantiCell 700 dynamic imaging microscopy
system (Visitech Int. Ltd., UK), with 30^40 MCF-7 cells per ¢eld as
previously described [15]. The cells were cultured on glass coverslips,
washed, and incubated at 37‡C for 60 min in PBS^calcium-free
HEPES medium (20 mM HEPES/Tris, pH 7.4, 5.4 mM KCl, 2 mM
Na2PO4, 0.8 mM MgCl2, and 5 mM glucose) containing 5 WM Fura-
2/AM. Before analysis, the cells were washed twice with the same
bu¡er. After background recording for 40 s (20 images), the experi-
ment was initiated by adding di¡erent concentrations of IGFBP-3,
IGFBP-1 or IGFBP-5. Fluorescence images were obtained at intervals
of 2 s and intracellular Ca2þ concentrations were calculated over 200 s
from the ratio of the £uorescence intensities at 340 and 380 nm on a
pixel basis. The dose^response curve for intracellular calcium concen-
trations was obtained by integrating the area under the curve (mea-
suring Ca2þ transient peaks plotted as a function of time for each ¢eld
from the addition of IGFBP-3 until the end of image recording, 200 s)
and averaging the £uorescence from the whole ¢eld of cells chosen.
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Ca2þ stimulation curves were determined for each concentration of
IGFBP-3 tested.
3. Results
Addition of 20 nM IGFBP-3 to MCF-7 cells increased in-
tracellular free calcium concentrations within 2^4 s, a return
to basal levels occurring 20^30 s later (Fig. 1). The response to
IGFBP-3 was therefore transient, where calcium was released
into the cytoplasm from intracellular stores and then re-ab-
sorbed. The viability of the cells in terms of calcium response
was con¢rmed by their reaction to thapsigargin (1 WM) which
induced total and irreversible calcium release from intracellu-
lar stores. As shown in Fig. 2, the response was dose-depen-
dent: it was evident using 1^2 nM IGFBP-3 and maximal
using 20^50 nM IGFBP-3; ED50 = 3.02 nM.
In view of the rapid response to IGFBP-3, internalization
seemed improbable and the existence of a membrane receptor
for IGFBP-3 most likely. We therefore set out to characterize
the binding between IGFBP-3 and the cell surface in MCF-7
cells. Fig. 3 shows the competition curve and Scatchard anal-
ysis for a typical experiment. The mean association constant
calculated from four experiments was 0.4U 0.03U108 M31
and the mean number of binding sites was 4.9U105 sites/
cell. Non-speci¢c binding was 7^9%. Binding to the cell sur-
face (Fig. 3) and the ability to increase calcium concentrations
(Fig. 1) appeared to be speci¢c to IGFBP-3 in MCF-7 cells,
since two other IGFBPs, IGFBP-1 and IGFBP-5 (the latter
being structurally the most similar to IGFBP-3) had no e¡ect
(Fig. 4).
Fig. 1. IGFBP-3 increases intracellular calcium concentrations in MCF-7 cells. MCF-7 cells cultured on glass coverslips were incubated with
Fura-2/AM. After background recording for 40 s to determine basal intracellular calcium concentrations as described in Section 2, cells were
incubated (A) with IGFBP-3 (20 nM), then (B) with thapsigargin (1 WM). The results of a typical experiment are shown, in which two repre-
sentative cells (blue and yellow lines) or the whole ¢eld (red line) were analyzed and intracellular calcium quanti¢ed. The slides from left to
right show representative views of the cells (a) before addition of IGFBP-3, (b) after addition of IGFBP-3, (c) after return to basal levels and
before addition of thapsigargin, and (d) after addition of thapsigargin.
Table 1
E¡ects of IGF-I/IGFBP-3 and heparin/IGFBP-3 complexes on intra-
cellular calcium concentrations in MCF-7 cells
Treatment Cytosolic Ca2þ (percent of maximum)
IGFBP-3 (20 nM) 100
Heparin (200 Wg/ml) 0
IGF-I (1 WM) 0
Heparin/IGFBP-3 94.7
IGF-I/IGFBP-3 170
MCF-7 cells were incubated with IGF-I (1 WM), heparin (200 Wg/
ml), or IGFBP-3 (20 nM) either alone or previously incubated for
50 min at room temperature with either IGF-I (1 WM) or heparin
(200 Wg/ml). Intracellular calcium concentrations were measured as
described in Section 2. Results of a typical experiment are presented
(mean for three independent points).
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In many cases, transient increases of intracellular calcium
depend on heterotrimeric G protein activation, so we tested a
G protein inhibitor for its ability to block the IGFBP-3-in-
duced increase in cytosolic calcium. This proved true for per-
tussis toxin, indicating that the speci¢c receptor activated by
IGFBP-3 in MCF-7 cells was probably coupled to a G protein
(Fig. 5).
With a view to locating the position of the putative receptor
binding site, we investigated the di¡erence between the e¡ects
of IGFBP-3 alone and complexed with either heparin or IGF-
I on the IGFBP-3-induced cytosolic calcium increase. Neither
IGF-I (1 WM) nor heparin (200 Wg/ml) alone changed intra-
cellular calcium concentrations (Table 1). The IGFBP-3^hep-
arin complex had the same e¡ect on calcium levels as IGFBP-
3 alone and the IGFBP-3^IGF-I complex induced a larger
calcium increase than IGFBP-3 alone.
4. Discussion
This study provides the ¢rst evidence that an IGF binding
protein, IGFBP-3, is capable of speci¢cally transmitting an
intracellular signal, giving rise to an increase in cytosolic
free calcium in MCF-7 breast carcinoma cells. The kinetics
of this transient increase were extremely rapid, suggesting that
internalization of IGFBP-3 was highly unlikely and therefore
that a membrane IGFBP-3 receptor capable of mediating in-
tracellular signalling must exist. The results of the speci¢c
binding experiments were reproducible, with high non-speci¢c
binding (7^9%) owing to the stickiness of radiolabelled
IGFBP-3. Consequently, at 200 nM IGFBP-3, displacement
of [125I]IGFBP-3 remained incomplete and the true associa-
tion constant was probably underestimated and the calculated
Fig. 2. The e¡ect of IGFBP-3 on intracellular calcium concentra-
tions in MCF-7 cells is dose-dependent. MCF-7 cells cultured on
glass coverslips were incubated with Fura-2/AM. After background
recording for 40 s to determine basal intracellular calcium concen-
trations as described in Section 2, cells were incubated with IGFBP-
3. Separate and independent experiments were performed for each
IGFBP-3 concentration. Dose^response curves for intracellular calci-
um concentrations were established as described in Section 2.
Fig. 3. rhIGFBP-3 binds to MCF-7 cells in monolayer culture.
A: Cells were incubated with [125I]IGFBP-3 in the presence of either
various concentrations of IGFBP-3 (0^5 WM) or 5 WM of IGFBP-1
or -5. The displacement curve obtained after subtraction of non-spe-
ci¢c binding determined in the presence of 400 nM IGFBP-3 is pre-
sented. Speci¢c binding at 0 and 1 nM IGFBP-3 was 8.2% of total
[125I]IGFBP-3. B: Scatchard plot of the data. Results of a typical
experiment.
Fig. 4. Neither IGFBP-1 nor IGFBP-5 a¡ect intracellular calcium
concentrations in MCF-7 cells. MCF-7 cells were incubated (A)
with either 20 nM IGFBP-1 (lower panel) or 20 nM IGFBP-5
(upper panel), then (B) with IGFBP-3 (20 nM) and (C) treated with
thapsigargin (1 WM). Intracellular calcium concentrations were mea-
sured as described in Section 2. The results of a typical experiment
are shown in which the whole ¢eld was analyzed and intracellular
calcium quanti¢ed.
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number of binding sites, overestimated. In their work on
breast cancer cell lines, Yamanaka et al. [14] found a similar
number of binding sites to ours in Hs578T cells, but for
MCF-7 cells they found 20^30 times fewer sites with three
times stronger a⁄nity. However, these values were the highest
ones calculated from curvilinear plots, suggesting a two-site
binding model. In our experiments, the Scatchard plots were
apparently linear, which probably means a smaller proportion
of high-a⁄nity binding sites in our cells than in those of
Yamanaka et al. [14].
IGFBP-3 provoked a rise in intracellular calcium following
activation of a pertussis-sensitive G-coupled receptor. In view
of the speci¢city of pertussis toxin, it would seem that the
IGFBP-3 receptor may be speci¢cally coupled to a Gi protein
in MCF-7 cells. The nature of both the Gi protein and the
receptor are currently under investigation. It is noteworthy
that we [11] and others [7] have shown that IGFBP-3 can
bind to cell surface proteins with an apparent molecular
mass of 30^40 kDa, which coincides with that of most
G protein-coupled receptors. Furthermore, it has recently be-
come evident that Gi proteins play an important role in the
IGF signalling pathway: GLQ proteins mediate MAP kinase
activation by IGF-I [16,17] and activation of a Gi protein is a
prerequisite for IGF-I-induced proliferation and di¡erentia-
tion in 3T3-L1 adipocytes and HIRcB cells [18]. We previ-
ously demonstrated that IGFBP-3 can down-regulate the
IGF-I signalling pathway [11] and it is conceivable that this
e¡ect and the so-called IGF-independent e¡ects of IGFBP-3
(for review [6]) may result from activation of this IGFBP-3
receptor coupled to a pertussis toxin-sensitive G protein.
In the experiments described above, we used commercial
(N109D)-IGFBP-3 (recombinant Escherichia coli protein).
The same results were obtained using either wild-type re-
combinant E. coli IGFBP-3 or a baculoviral glycosylated
IGFBP-3 preparation (data not shown). This indicates that
the N109D mutation caused no experimental artefacts and
that glycosylation made no di¡erence in the responses ob-
served to IGFBP-3. Since neither IGFBP-1 nor IGFBP-5
(structurally the most closely related to IGFBP-3) competes
for the binding of [125I]IGFBP-3 to the cell surface receptor
and had any e¡ect on intracellular calcium concentrations in
MCF-7 cells, it can be concluded that the mechanism of ac-
tion of IGFBP-3 is speci¢c. From this and a previous study
suggesting that the mid-region of IGFBP-3 is probably re-
Fig. 5. IGFBP-3 increases intracellular calcium concentrations via a pertussis toxin-sensitive pathway in MCF-7 cells. MCF-7 cells cultured on
glass coverslips were treated with or without 200 ng/ml pertussis toxin (PTX) for 16 h at 37‡C and incubated with Fura-2/AM. After back-
ground recording for 40 s to determine basal intracellular calcium concentrations as described in Section 2, cells were incubated (A) with
IGFBP-3 (20 nM), then (B) with thapsigargin (1 WM). The results of a typical experiment are shown, in which two representative cells (green
and yellow lines) or the whole ¢eld (red line) were analyzed and intracellular calcium quanti¢ed. The slides from left to right show representa-
tive views of the cells (a) before addition of IGFBP-3, (b) after addition of IGFBP-3, (c) after return to basal levels and before addition of
thapsigargin, and (d) after addition of thapsigargin.
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sponsible for IGFBP-3 binding to the cell surface [14], it can
be hypothesized that the binding site for the IGFBP-3 recep-
tor would be situated in the least conserved region among the
IGFBPs, the central domain of IGFBP-3. An explanation for
the observation that IGFBP-3 complexed with IGF-I was
more e¡ective in increasing calcium concentrations than
IGFBP-3 alone may lie in greater conformational stability
conferred by complex formation with IGF-I and hence more
favorable interaction with the receptor. This would be consis-
tent with the physiological potential of such a mechanism,
particularly since, for the most part, IGFBP-3 circulates in
the cellular environment as an IGF^IGFBP-3 complex. The
greater e⁄cacy of this complex also indicates that IGF-I does
not mask the binding site on IGFBP-3 for its receptor.
Although our binding sites appear to be similar to those de-
scribed by Yamanaka et al. [14], it has been reported in other
studies [19,20] that IGF-I binding to IGFBP-3 diminishes, but
does not totally inhibit, its interaction with cell surface bind-
ing sites. It would seem that in the latter model su⁄cient
binding sites could remain unblocked for IGFBP-3/IGF-I
complexes to a¡ect intracellular calcium. As regards the sim-
ilar e¡ects on calcium levels of IGFBP-3 complexed with hep-
arin and IGFBP-3 alone, the implication would be that the
IGFBP-3 binding site for its receptor is nowhere close to the
heparin binding site which is situated in the C-terminal region.
Heparin has been shown to inhibit IGFBP-3 binding to the
membranes of GM-10 ¢broblasts and C6 glioma cells [21],
suggesting that it might compete for binding to structurally
similar heparan sulfate proteoglycans on the cell surface.
However, the inhibition of IGFBP-3 binding by heparin was
not total [21] and it would seem that IGFBP-3 may bind to
sites other than the cell surface heparan sulfate proteoglycans.
In our cell model, heparin clearly failed to inhibit the IGFBP-
3-induced increase in intracellular calcium and in this instance
IGFBP-3 action could not involve heparan sulfate proteogly-
cans.
In conclusion, our results reveal an essential molecular
mechanism of rapid action for IGFBP-3 in MCF-7 cells, pro-
viding direct evidence of signalling pathways that it activates
and opening new doors in research on the so-called IGF-in-
dependent activities of IGFBP-3.
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